EBS (Emergent BioSolutions) Cyclically Adjusted Book per Share: $22.61 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBS Emergent BioSolutions Inc EBS
61 GF Score
Price $5.31
GF Value $5.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Emergent BioSolutions Cyclically Adjusted Book per Share?

Emergent BioSolutions EBS -29.58% 61 Cyclically Adjusted Book per Share is $22.61 as of Jun. 2026. GuruFocus rates EBS with a GF Score™ of 61/100 and a GF Value™ of $5.62 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Emergent BioSolutions's adjusted book value per share for the three months ended in Jun. 2026 was $6.655. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $22.61 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Emergent BioSolutions's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 0.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Emergent BioSolutions was 13.50% per year. The lowest was 0.30% per year. And the median was 10.55% per year.

As of today (2026-08-07), Emergent BioSolutions's current stock price is $5.31. Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $22.61. Emergent BioSolutions's Cyclically Adjusted PB Ratio of today is 0.23.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Emergent BioSolutions was 8.34. The lowest was 0.07. And the median was 2.56.


Emergent BioSolutions  (NYSE:EBS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Emergent BioSolutions's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.31/22.61
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Emergent BioSolutions was 8.34. The lowest was 0.07. And the median was 2.56.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Emergent BioSolutions Cyclically Adjusted Book per Share Related Terms


Emergent BioSolutions Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Cyclically Adjusted Book per Share Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.72 22.46 23.26 23.09 22.66

Emergent BioSolutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.13 23.04 22.66 22.76 22.61

EBS vs EOLS, ELTP, AKBA: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted PB Ratio falls into.


EBS
61GF Score
Emergent BioSolutions Inc EBS
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emergent BioSolutions's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.655/333.9520*333.9520
=6.655

Current CPI (Jun. 2026) = 333.9520.

Emergent BioSolutions Quarterly Data

Book Value per Share CPI Adj_Book
201609 13.526 241.428 18.710
201612 14.694 241.432 20.325
201703 14.905 243.801 20.416
201706 15.097 244.955 20.582
201709 16.039 246.819 21.701
201712 18.466 246.524 25.015
201803 17.693 249.554 23.677
201806 18.761 251.989 24.863
201809 19.261 252.439 25.480
201812 19.744 251.233 26.245
201903 19.212 254.202 25.239
201906 19.165 256.143 24.987
201909 20.058 256.759 26.088
201912 21.054 256.974 27.361
202003 20.564 258.115 26.606
202006 22.662 257.797 29.357
202009 23.613 260.280 30.297
202012 27.250 260.474 34.937
202103 28.410 264.877 35.819
202106 28.747 271.696 35.334
202109 28.356 274.310 34.521
202112 31.413 278.802 37.627
202203 31.256 287.504 36.306
202206 30.325 296.311 34.177
202209 29.044 296.808 32.679
202212 27.699 296.797 31.167
202303 23.861 301.836 26.400
202306 18.461 305.109 20.206
202309 13.459 307.789 14.603
202312 12.439 306.746 13.542
202403 12.670 312.332 13.547
202406 7.302 314.175 7.762
202409 9.405 315.301 9.961
202412 8.886 315.605 9.403
202503 10.141 319.799 10.590
202506 9.985 322.561 10.338
202509 11.053 324.800 11.364
202512 10.031 324.054 10.337
202603 10.098 330.213 10.212
202606 6.655 333.952 6.655

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $22.61 mean?
Emergent BioSolutions (EBS) has a Cyclically Adjusted Book per Share of $22.61 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Cyclically Adjusted Book per Share too high?
Emergent BioSolutions' current Cyclically Adjusted Book per Share is $22.61. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Cyclically Adjusted Book per Share compare to EOLS and ELTP?
Emergent BioSolutions' Cyclically Adjusted Book per Share of $22.61 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Cyclically Adjusted Book per Share is $22.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (EBS) is currently considered Fairly Valued. The stock's GF Value™ is $5.62, compared to a current price of $5.31 — trading 5.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is $22.61. Emergent BioSolutions' overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Emergent BioSolutions (EBS), the current Cyclically Adjusted Book per Share is $22.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (EBS) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be undervalued. The current stock price of $5.31 is trading 5.5% below its estimated GF Value™ of $5.62. GuruFocus considers Emergent BioSolutions to be Fairly Valued.

Key valuation signals for EBS:

  • Cyclically Adjusted Book per Share: $22.61
  • GF Value™: $5.62 vs. price of $5.31 (5.5% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the EBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emergent BioSolutions Business Description

Other Exchanges 0IGA:UKER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score

Get the complete analysis for EBS

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.31
Price
$5.62
GF Value